Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.

Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, Verzoni E, Di Cosimo S, Locati LD, Cristofanilli M, Daidone MG, Cappelletti V.

Semin Cancer Biol. 2019 Oct 15. pii: S1044-579X(19)30170-1. doi: 10.1016/j.semcancer.2019.10.008. [Epub ahead of print] Review.

2.

Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker.

Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L, Vitale MG, Fanotto V, Barban S, Cinausero M, Bonotto M, Gerratana L, Mansutti M, Curcio F, Fasola G, Minisini AM, Puglisi F.

Cancers (Basel). 2019 Aug 24;11(9). pii: E1243. doi: 10.3390/cancers11091243.

3.

APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.

Malfatti MC, Gerratana L, Dalla E, Isola M, Damante G, Di Loreto C, Puglisi F, Tell G.

J Exp Clin Cancer Res. 2019 Jul 15;38(1):309. doi: 10.1186/s13046-019-1294-9.

4.

Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.

Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.

Int J Mol Sci. 2019 Jul 10;20(14). pii: E3390. doi: 10.3390/ijms20143390. Review.

5.

Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.

Gerratana L, Davis AA, Shah AN, Lin C, Corvaja C, Cristofanilli M.

Curr Treat Options Oncol. 2019 Jun 29;20(8):68. doi: 10.1007/s11864-019-0667-9. Review.

PMID:
31256282
6.

Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer.

Basile D, Gerratana L, Buonadonna A, Garattini SK, Perin T, Grassilli E, Miolo G, Cerrito MG, Belluco C, Bertola G, De Paoli A, Cannizzaro R, Lavitrano M, Puglisi F, Canzonieri V.

Cancers (Basel). 2019 Jun 24;11(6). pii: E880. doi: 10.3390/cancers11060880.

7.

Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside.

Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F.

Cancers (Basel). 2019 Jun 20;11(6). pii: E857. doi: 10.3390/cancers11060857. Review.

8.

Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach.

Cortiula F, De Maglio G, Cangi MG, Gerratana L, Lisanti C, Bonura S, Fasola G, Follador A.

Ann Transl Med. 2019 Jan;7(1):14. doi: 10.21037/atm.2018.12.42.

9.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
10.

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.

Basile D, Parnofiello A, Vitale MG, Cortiula F, Gerratana L, Fanotto V, Lisanti C, Pelizzari G, Ongaro E, Bartoletti M, Garattini SK, Andreotti VJ, Bacco A, Iacono D, Bonotto M, Casagrande M, Ermacora P, Puglisi F, Pella N, Fasola G, Aprile G, Cardellino GG.

J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):368-377. doi: 10.1002/jcsm.12368. Epub 2019 Feb 4.

11.

Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma.

Iacono D, Basile D, Gerratana L, Vitale MG, Pelizzari G, Cinausero M, Poletto E, Puglisi F, Fasola G, Minisini AM.

Melanoma Res. 2019 Oct;29(5):510-515. doi: 10.1097/CMR.0000000000000584.

PMID:
30702508
12.

Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F.

Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Review.

PMID:
30682661
13.

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G.

J Geriatr Oncol. 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009. Epub 2018 Dec 11.

PMID:
30551958
14.

Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation.

Pelizzari G, Gerratana L, Basile D, Fanotto V, Bartoletti M, Liguori A, Fontanella C, Spazzapan S, Puglisi F.

Cancer Treat Rev. 2019 Jan;72:7-14. doi: 10.1016/j.ctrv.2018.10.014. Epub 2018 Oct 30. Review.

PMID:
30414986
15.

Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models.

Liu X, Taftaf R, Kawaguchi M, Chang YF, Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel DB, Tsui E, Adorno-Cruz V, Chirieleison SM, Cao Y, Harney AS, Patel S, Patsialou A, Shen Y, Avril S, Gilmore HL, Lathia JD, Abbott DW, Cristofanilli M, Condeelis JS, Liu H.

Cancer Discov. 2019 Jan;9(1):96-113. doi: 10.1158/2159-8290.CD-18-0065. Epub 2018 Oct 25.

PMID:
30361447
16.

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.

Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.

Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.

PMID:
30259975
17.

Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.

De Carlo E, Gerratana L, De Maglio G, Buoro V, Cortiula F, Gurrieri L, Isola M, Fasola G, Puglisi F, Pizzolitto S, Rizzato S.

J Neurooncol. 2018 Dec;140(3):559-568. doi: 10.1007/s11060-018-2981-7. Epub 2018 Aug 21.

PMID:
30132165
18.

Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study : Complementary and alternative medicine in oncology.

Bozza C, Gerratana L, Basile D, Vitale MG, Bartoletti M, Agostinetto E, Russo S, Follador A, De Carlo E, Pella N, Sottile R, Fasola G, Puglisi F.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2029-2047. doi: 10.1007/s00432-018-2709-2. Epub 2018 Jul 24.

PMID:
30043280
19.

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G.

Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11. Review.

20.

Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.

Iacono D, Cinausero M, Gerratana L, Angione V, Scott CA, De Maglio G, Pizzolitto S, Di Loreto C, Puglisi F, Fasola G, Minisini AM.

Melanoma Res. 2018 Dec;28(6):547-554. doi: 10.1097/CMR.0000000000000462.

PMID:
29794562
21.

Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F.

Breast. 2018 Aug;40:45-52. doi: 10.1016/j.breast.2018.04.011. Epub 2018 Apr 19.

PMID:
29679936
22.

Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.

Ongaro E, Gerratana L, Cinausero M, Pelizzari G, Poletto E, Giangreco M, Andreetta C, Pizzolitto S, Di Loreto C, Minisini AM, Mansutti M, Russo S, Fasola G, Puglisi F.

Future Oncol. 2018 Apr;14(9):849-859. doi: 10.2217/fon-2017-0384. Epub 2018 Mar 12.

PMID:
29527957
23.

MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S.

Future Oncol. 2018 Apr;14(8):699-707. doi: 10.2217/fon-2017-0437. Epub 2018 Mar 9.

PMID:
29521523
24.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. No abstract available.

25.

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G.

Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.

26.

Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.

Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, Gerratana L, Puglisi F.

Cancer Treat Rev. 2017 Dec;61:15-22. doi: 10.1016/j.ctrv.2017.09.006. Epub 2017 Oct 6. Review.

PMID:
29078133
27.

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G.

Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: Future Oncol. 2018 Mar;14 (6):577.

PMID:
28976226
28.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. Erratum in: Oncologist. 2018 Feb;23 (2):272.

29.

Determinants of Last-line Treatment in Metastatic Breast Cancer.

Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V, Buoro V, Basile D, Vitale MG, Rihawi K, Fasola G, Puglisi F.

Clin Breast Cancer. 2018 Jun;18(3):205-213. doi: 10.1016/j.clbc.2017.07.008. Epub 2017 Jul 14.

PMID:
28781022
30.

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.

Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F.

Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Review.

PMID:
28092723
31.

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F.

Breast. 2017 Feb;31:114-120. doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9.

PMID:
27837704
32.

Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example.

Gerratana L, De Maglio G, De Pellegrin A, Follador A, Rihawi K, Pizzolitto S, Puglisi F, Fasola G.

Onco Targets Ther. 2016 Aug 30;9:5399-404. doi: 10.2147/OTT.S104748. eCollection 2016.

33.

Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy.

Puglisi F, Agostinetto E, Gerratana L, Bozza C, Cancian M, Iannelli E, Ratti G, Cinieri S, Numico G.

Future Oncol. 2017 Feb;13(3):233-248. doi: 10.2217/fon-2016-0383. Epub 2016 Sep 12.

34.

Do platinum salts fit all triple negative breast cancers?

Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F.

Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11. Review.

PMID:
27343437
35.

In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.

Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D.

Breast Cancer Res. 2016 Mar 9;18(1):30. doi: 10.1186/s13058-016-0687-3.

36.

[Complementary and alternative medicine in oncology].

Bozza C, Agostinetto E, Gerratana L, Puglisi F.

Recenti Prog Med. 2015 Dec;106(12):601-7. doi: 10.1701/2094.22648. Review. Italian.

PMID:
26780069
37.

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, Puglisi F.

Oncologist. 2015 Jul;20(7):719-24. doi: 10.1634/theoncologist.2015-0002. Epub 2015 May 27.

38.

Pattern of metastasis and outcome in patients with breast cancer.

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F.

Clin Exp Metastasis. 2015 Feb;32(2):125-33. doi: 10.1007/s10585-015-9697-2. Epub 2015 Jan 29.

PMID:
25630269
39.

Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F.

Oncologist. 2014 Jun;19(6):608-15. doi: 10.1634/theoncologist.2014-0002. Epub 2014 May 2.

40.

Factors affecting patient's perception of anticancer treatments side-effects: an observational study.

Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, Deroma L, Sottile R, Fasola G, Puglisi F.

Expert Opin Drug Saf. 2014 Feb;13(2):139-50. doi: 10.1517/14740338.2013.830710. Epub 2013 Sep 27.

PMID:
24073801
41.

Risk factors and survival outcomes in patients with brain metastases from breast cancer.

Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C, Fasola G, Puglisi F.

Clin Exp Metastasis. 2013 Dec;30(8):951-6. doi: 10.1007/s10585-013-9594-5. Epub 2013 Jun 18.

PMID:
23775210

Supplemental Content

Loading ...
Support Center